Two recent developments have heightened investors' anxiety about the CBD stock. Are the worries overblown?
Momentum continues from the drugmaker's royalty deal announced earlier this week despite a big public stock offering.
Investors reacted positively to the drugmaker's late-stage clinical results.
Investors aren't happy with the company's mixed results from a midstage study of Oral Korsuva.
International medical cannabis sales was one of only a few bright spots in Aurora's ugly Q1 results. Now that bright spot appears to be largely snuffed out, at least temporarily.
But the big Canadian cannabis producer has a safety net that most of its rivals don't.
The latest ICER report doesn't paint AbbVie's new rheumatoid arthritis drug Rinvoq in as favorable a light as hoped.
Not every pot stock floundered in November. These three delivered solid double-digit percentage gains.
Investors are excited about a big royalty deal for the biotech's lead pipeline candidate.
This small tech stock should benefit from an unstoppable trend: explosive growth in data.
Why bother with Aurora when these pot stocks have better revenue growth, better bottom lines, and better growth prospects?
These biotech stocks cover all the bases, from great dividends to promising pipelines.
These stocks are great picks to own regardless of which turns the market takes.
Which stock wins in a matchup between these two healthcare giants?
Which stock wins in a matchup between a top Canadian cannabis producer and a leading U.S. gardening supply company?
Momentum is continuing for the biotech after an announcement of positive clinical results and buying by key insiders earlier this month.
A major contract loss in Kentucky is weighing heavily on the managed-care stock.
J&J's competitive advantages aren't what they used to be. But does that change the appeal of the blue chip stock?
The Canadian cannabis producer enjoyed a nice rebound -- but only a temporary one.
A combination of several factors could be behind the biotech's big gain.